ImmunoGen ( IMGN -4% ) appoints Sandra E. Poole as SVP, Technical Operations reporting to CEO Daniel Junius. She joins the firm from Genzyme where she was SVP of biologics manufacturing. Post your comment!
Genzyme (NYSE: SNY ) (NASDAQ: GCVRZ ) presents interim results from an extension study of Lemtrada ( alemtuzumab ) today at the European
In an interview with Reuters , Genzyme 's (NYSE: SNY ) (NASDAQ: GCVRZ ) chief of its multiple sclerosis franchise Bill Sibold says his firm intends to be a leader
PARIS, Sept 11 (Reuters) - Sanofi rare disease unit Genzyme said its Lemtrada multiple sclerosis (MS) drug showed continued efficacy for four years in more than two thirds of patients and that no new safety risks had been identified in its latest studies.
PARIS, Sept 11 (Reuters) - Sanofi rare disease unit Genzyme hopes to become a leader in the multiple sclerosis (MS) field with the help of new products developed in-house but also through...
continues. I think there is going to be a theme, which we've seen in our portfolio, where historically names like Genzyme , Chiron, Millennium, and ImClone have all been acquired, and what we're seeing today is Big Pharma continue to chase
the Medley, Chattem, Merial, and Genzyme acquisitions all have generated returns ..... than four years. Additionally, the Genzyme acquisition shows how Sanofi avoided ..... value rights, or CVR, to appease Genzyme . Further, Viehbacher's decision
quarterly results. The company's updated guidance on an improving pipeline along with steady growth from emerging markets, Genzyme products, consumer health, vaccines, and diabetes drugs increases our conviction behind our wide moat rating for the
growth continued to perform well, with particular strength from diabetes drug Lantus, which was up 18% year over year. Genzyme products and emerging markets also continued to post steady gains. However, generic competition to cardiovascular drug
challenging macroeconomic conditions. LabCorp's purchases of Genzyme Genetics' diagnostics unit and Orchid Cellmark in 2010-11 ..... times sales for Medtox, and it paid 2.5 times sales for Genzyme 's diagnostics in 2010--considerably lower compared